Gene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
CDPQ acquires stake in Sebia
Latest NewsCaisse de dépôt et placement du Québec (CDPQ) is set to acquire a minority stake in diagnostic electrophoresis player Sebia Group from private equity investors Astorg and Montagu.
Swiss Roivant bags US$1.1bn financing
Latest NewsSerial drug licensee Roivant Sciences GmbH (Basel) has cashed in US$1.1bn (€937m) in an equity financing led by SoftBank Vision Fund and co-financed by existing investor Dexcel Pharma.
Voluntary health agency jump-starts Selvita’s SEL120 programme
Latest NewsThe Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukaemia (AML).
LEO orders Hitgen to discover new leads
Latest NewsIn a multi-year collaboration with LEO Pharma A/S, Chinese Hitgen is poised to discover novel small molecule leads for multiple therapeutic targets chosen by the Danish skin treatment specialist.
Acquisition: Thermo enters CMO world
BackgroundLab equipment giant Thermo Fisher Scientific Inc. is growing even bigger.
Uniqure’s new COO to oversee GMP
AppointmentsGene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
Vernalis receives next veto by FDA
Latest NewsBritish biotech company Vernalis has to deal with another Complete Response Letter by US authority FDA – this time regarding the New Drug Application for its cough and cold treatment CCP-08.
Hansa’s immunomodulatory enzyme does the job
Latest NewsSweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
Biosimilars labelling
OpinionEuropaBio has developed recommendations for changes to the Summary of Product Characteristics (SmPC) of biosimilars that would result in an enhanced level of transparency for the label.
TC Biopharm gets €4m Horizon2020 grant
Latest NewsThe Scottish biotech company TC Biopharm (TCB) has been awarded a €4m grant from the European Union’s Horizon 2020 programme.